Precision medicine in colorectal cancer: the molecular profile alters treatment strategies - Wikidata - wikimedia - TriplyDB

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies

http://www.wikidata.org/entity/Q26795558

about

RAS isoforms and mutations in cancer at a glance Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis.ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.3D Miniaturization of Human Organs for Drug Discovery.In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening.Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.Analysis of a gene panel for targeted sequencing of colorectal cancer samples.HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells.Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling.

P2860

Q28070394-2F707163-29E2-4A0C-9502-62BA1182D2E3 Q28079309-BDFF72F1-EDED-4C4D-8A26-AE6173E26FBA Q30235450-3E82711C-DFA1-47ED-887B-8E2E3C1874D6 Q33768220-997D6F11-4B98-416C-AEF2-637F8DC69130 Q35988684-6F7A90C2-F97B-44D1-9473-4A1ED3777CFE Q37725589-822425E7-B29E-4A83-86EE-31F1B3157FD8 Q40077046-F452AFC1-F8DC-45E4-A151-DC5146FC437D Q47698887-06D2A6CC-F8E4-40B5-8DC4-6AD1162A5BD9 Q49542418-42ED2D11-DF68-4321-860A-65BBB4B5490D Q50090313-6385CE0F-976A-4799-9766-B64C232DD440 Q50420743-441A9D68-96BC-4792-8172-93D9310F0627 Q52707747-7CD6568C-F33B-427D-BFEB-2523D0DF54C2 Q55272385-068F7CB1-FD6D-472C-98E5-70637E65430B

P2860

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies

http://www.wikidata.org/entity/Q26795558

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Precision medicine in colorect ...... le alters treatment strategies

@ast

Precision medicine in colorect ...... le alters treatment strategies

@en

Precision medicine in colorect ...... le alters treatment strategies

@nl

type

label

Precision medicine in colorect ...... le alters treatment strategies

@ast

Precision medicine in colorect ...... le alters treatment strategies

@en

Precision medicine in colorect ...... le alters treatment strategies

@nl

prefLabel

Precision medicine in colorect ...... le alters treatment strategies

@ast

Precision medicine in colorect ...... le alters treatment strategies

@en

Precision medicine in colorect ...... le alters treatment strategies

@nl

P1433

Q26795558-223666E2-519D-49E1-8946-E5510B14CE68

P1476

Q26795558-659365BB-165E-4B67-931C-2ECCCBF13FA9

P2093

Q26795558-2A51693F-DD6D-4E95-B08F-0229B38187B4

Q26795558-336965A1-90AC-4F04-A652-E38024A68B95

Q26795558-648621C2-E78D-4444-83D5-2B69BFA9EDBB

Q26795558-7D615440-6891-4848-84A6-56F659542856

Q26795558-7F08C851-45D3-4417-8A5A-9247172B069D

Q26795558-9D3E8CF9-E808-4F8C-B37F-4ADB7C4E71BC

Q26795558-D515FA2A-5971-4CF6-AAB0-4A7AAA1565A4

Q26795558-E6E13A61-E799-4604-A645-5C6D790A81EF

P2860

Q26795558-0018E9D6-0704-44AA-9862-9AF4D7379FC5

Q26795558-05166008-BB68-4F62-B200-8EDFCA1C05D8

Q26795558-0F2B751E-275E-4210-8D96-EBC437D007A5

Q26795558-100AC613-D8EE-4853-8656-3F6DDD8C4469

Q26795558-236A7418-375F-401A-9DC7-9B0EFCE43D13

Q26795558-25402651-69D8-4A80-B1D1-F1A2325C16B3

Q26795558-26B87B44-E866-454E-8262-AA41B541799F

Q26795558-328C14B8-744C-4250-9F03-11B6AB3C3968

Q26795558-33AC538B-E0EC-4F4E-B3FB-BE5F805D9B32

Q26795558-47415FA8-FD44-49FB-9AD6-4C209E576DCA

P304

Q26795558-C2B6B976-7FF4-4987-B15E-2F6344BAFD0B

P31

Q26795558-F6C489ED-6FDE-43F3-B8F8-90F513AB5DCB

P3181

Q26795558-A4B0D4E5-AC67-49FF-AAD7-FFCF5E108BE4

P356

Q26795558-A68F72C9-F0E2-442A-9CA3-391D14888D51

P407

Q26795558-0E03ADD6-92B9-4B14-AC1C-BC7DDD150395

P433

Q26795558-C9E44F3D-7A3F-4E46-BF65-E2B2CE0872D7

P478

Q26795558-DA0B5AE0-7DD0-4CB1-8C3D-4BAB41EFA462

P577

Q26795558-768D9675-2930-4C2C-AA3D-BEFD9692FF8A

P698

Q26795558-0F768984-C149-486D-9385-B5B010B380D1

P921

Q26795558-CB74C40B-6A01-4061-B2E7-E269A856C1FE

P932

Q26795558-AEA5EAB4-04AE-43EF-9F59-0F38BFC7CD49

P3181

P356

1758834015591952

P1433

Therapeutic advances in medical oncology

P1476

Precision medicine in colorect ...... le alters treatment strategies

@en

P2093

Daniel L Mulkerin

http://www.w3.org/2001/XMLSchema#string

Dustin A Deming

http://www.w3.org/2001/XMLSchema#string

Kristina A Matkowskyj

http://www.w3.org/2001/XMLSchema#string

Linda Clipson

http://www.w3.org/2001/XMLSchema#string

Ludmila L Cavalcante

http://www.w3.org/2001/XMLSchema#string

Nguyen H Tran

http://www.w3.org/2001/XMLSchema#string

Noelle K LoConte

http://www.w3.org/2001/XMLSchema#string

Sam J Lubner

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Mutations of the BRAF gene in human cancer

Cancer statistics, 2014

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

High frequency of mutations of the PIK3CA gene in human cancers

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

P304

252-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4906515

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/1758834015591952

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26327923

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4543854

http://www.w3.org/2001/XMLSchema#string